CALA - Calithera Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.6900
-0.0200 (-0.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.7100
Open2.6900
Bid0.0000 x 4000
Ask0.0000 x 1100
Day's Range2.6450 - 2.7350
52 Week Range2.4500 - 6.9000
Volume216,512
Avg. Volume332,667
Market Cap144.654M
Beta (3Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has completed patient enrollment in the ongoing CANTATA trial. CANTATA is a global, randomized double-blind clinical trial of the glutaminase inhibitor telaglenastat (CB-839) combined with cabozantinib, a standard of care, in patients with advanced or metastatic renal cell carcinoma (RCC) who have received one or two prior treatments. Exelixis, Inc. is providing cabozantinib for the trial through a material supply agreement with Calithera.

  • GlobeNewswire

    Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from its research and development portfolio will be featured in two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting 2019 in National Harbor, Maryland, taking place November 6-10. “The preclinical IL4I1 immuno-oncology program is an exciting new addition to our pipeline, and we are pleased that initial data from this program, as well as our ongoing CB-708 preclinical program, have been accepted for presentation at this high-profile meeting,” said Susan Molineaux, PhD, president and chief executive officer of Calithera.

  • GlobeNewswire

    New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced the presentation of new data from the investigational first-in-class oral arginase inhibitor INCB001158 as a monotherapy and in combination with the checkpoint inhibitor pembrolizumab in microsatellite stable (MSS) colorectal carcinoma patients. The data were presented during an oral Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2019 taking place in Barcelona, Spain (Abstract #440O).

  • GlobeNewswire

    Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, presented today supporting data for its previously reported positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The telaglenastat-everolimus combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile.

  • GlobeNewswire

    Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera to Present at the 2019 Cantor Global Healthcare Conference

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan M. Molineaux, Ph.D, the company’s founder, president and chief executive officer, will present at the 2019 Cantor Global Healthcare Conference at 1:45 p.m. ET on Friday, October 4, 2019 in New York. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.

  • GlobeNewswire

    Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in September. Susan M. Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present in Boston on Wednesday, September 4, 2019, at 1:50 p.m. Eastern Time. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity.

  • GlobeNewswire

    Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

    --Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 8, 2019-- SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 -- Calithera.

  • GlobeNewswire

    Calithera Biosciences to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s second quarter 2019 financial results will be released on Thursday, August 8, 2019. Company management will host a conference call on Thursday, August 8, 2019 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.

  • GlobeNewswire

    Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced treatment of the first patient in a Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with Pfizer’s CDK 4/6 inhibitor palbociclib, also known as Ibrance®.

  • GlobeNewswire

    Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., June 21, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock

    SOUTH SAN FRANCISCO, Calif., June 18, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by Calithera. In connection with this offering, Calithera expects to grant the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock.

  • GlobeNewswire

    Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile. Telaglenastat is the first glutaminase inhibitor to demonstrate clinical activity for the treatment of cancer.

  • GlobeNewswire

    Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights 

    --Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019-- SOUTH SAN FRANCISCO, Calif., May 09, 2019 -- Calithera Biosciences,.

  • GlobeNewswire

    Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced new preclinical data for the company’s CD73 inhibitor CB-708. The data will be presented today at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. CB-708 is a selective, oral inhibitor of CD73, an enzyme that synthesizes the immunosuppressive agent adenosine and is over-expressed in multiple tumor types.

  • GlobeNewswire

    Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib

    “The initiation of this clinical trial of telaglenastat in combination with talazoparib marks the first of two clinical trials that will evaluate telaglenastat with approved Pfizer therapeutics as part of this collaboration,” said Susan Molineaux, PhD, president and chief executive officer of Calithera.

  • GlobeNewswire

    Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., March 07, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera to Present at Cowen & Company 39th Annual Healthcare Conference

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan M. Molineaux, Ph.D, the company’s founder, president and chief executive officer, will present at the Cowen & Company 39th Annual Healthcare Conference at 10:40 a.m. ET on Tuesday, March 12, 2019 in Boston. Calithera is headquartered in South San Francisco, California. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire

    Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s fourth quarter 2018 financial results will be released on Thursday, March 7, 2019. Company management will host a conference call on Thursday, March 7, 2019 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.

  • GlobeNewswire

    Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019

    SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D, the company’s founder, president and chief executive officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Thursday, February 28, 2019 in New York City. Calithera is headquartered in South San Francisco, California. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire

    Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has initiated a Phase 1 clinical trial with CB-280, a novel, orally dosed arginase inhibitor being developed for the treatment of cystic fibrosis (CF). “The initiation of this Phase 1 study with CB-280 marks an important milestone in the advancement of our arginase program,” said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "We believe arginase inhibitors may offer an exciting new therapeutic approach for the treatment of patients with cystic fibrosis, independent of mutational status.

  • GlobeNewswire

    Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium

    SOUTH SAN FRANCISCO, Calif., Feb. 16, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • GlobeNewswire

    Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that it has completed patient enrollment in the ongoing Phase 2 ENTRATA trial. ENTRATA is a randomized clinical study of the glutaminase inhibitor CB-839 combined with everolimus versus placebo with everolimus for the treatment of advanced renal cell carcinoma (RCC).